Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17805 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Olufemi Aoko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Department, Beaumont Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Gastric Balloon, Bariatric Surgery. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beaumont Hospital Dublin, Charitable Infirmary Charitable Trust - Kieran Taaffe Bursary, Royal College of Surgeons in Ireland.
Abstract (Originalsprache)
Background
Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy ‐a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established.
Aim
To evaluate the effect of IGB as a treatment option in NAFLD.
Methods
We searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver‐related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non‐comparative studies; primary outcomes were liver‐related NAFLD surrogates.
Results
We included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): −3.0 [95% CI: −2.41 to −3.59], ALT: MD: −10.40 U/L [95% CI: −7.31 to −13.49], liver volume: MD ‐397.9 [95% CI: −212.78 to 1008.58] and liver steatosis: MD: −37.76 dB/m [95% CI: −21.59 to −53.92]. There were significant reductions in non‐liver‐related outcomes of body weight, BMI, glycated haemoglobin and HOMA‐IR.
Conclusion
Intragastric balloons may play an important role in addressing the treatment gap in NAFLD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatology Department, Beaumont Hospital, Dublin, Ireland.
- Gastroenterology Department, Beaumont Hospital, Dublin, Ireland.
- Royal College of Surgeons Ireland, Dublin, Ireland.
ORCID-Profile: Olufemi Aoko, Tobias Maharaj, Fiona Boland, Danny Cheriyan, John Ryan
Förderung
- Beaumont Hospital Dublin
- Charitable Infirmary Charitable Trust - Kieran Taaffe Bursary
- Royal College of Surgeons in Ireland
Zitieren
APA
Aoko, O., Maharaj, T., Boland, F., Cheriyan, D., & Ryan, J. (2024). Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17805
Vancouver
Aoko O, Maharaj T, Boland F, Cheriyan D, Ryan J. Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17805
BibTeX
@article{Aoko2024,
author = {Aoko, Olufemi and Maharaj, Tobias and Boland, Fiona and Cheriyan, Danny and Ryan, John},
title = {Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17805}
}
EUVIMED